{"id":"placebo-eyedrops","safety":{"commonSideEffects":[{"rate":null,"effect":"Minimal adverse events expected (non-active formulation)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo eyedrops are used as a control comparator in clinical trials to assess the efficacy of active ophthalmic treatments by isolating the pharmacological effect from psychological and contextual factors. They may produce measurable clinical improvements through patient expectation and the natural history of the underlying condition. This formulation is typically used in Phase 3 trials to establish that an investigational drug performs better than placebo alone.","oneSentence":"Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:54.261Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm)"}]},"trialDetails":[{"nctId":"NCT07495852","phase":"PHASE3","title":"Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2026-02-17","conditions":"Glaucoma","enrollment":510},{"nctId":"NCT06854393","phase":"PHASE2","title":"Lacripep for Corneal Wound Healing Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-05-23","conditions":"Corneal Epithelial Wound Healing","enrollment":88},{"nctId":"NCT04149210","phase":"PHASE3","title":"FLuorometholone as Adjunctive MEdical Therapy for TT Surgery (FLAME) Trial","status":"COMPLETED","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-08-19","conditions":"Trachomatous Trichiasis (TT), Eye Diseases, Eyelid Diseases","enrollment":2410},{"nctId":"NCT07490535","phase":"PHASE4","title":"This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Pittsburgh Research Institute","startDate":"2026-03","conditions":"Ocular Surface Disease, Dry Eye Syndrome (DES)","enrollment":36},{"nctId":"NCT05795699","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-03-30","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":107},{"nctId":"NCT05733572","phase":"PHASE2","title":"Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Benedetto Falsini","startDate":"2023-06-12","conditions":"Optic Pathway Glioma","enrollment":36},{"nctId":"NCT06089317","phase":"NA","title":"Traditional Chinese Medicine Ultrasonic Atomization Treatment for Dry Eye Disease","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2024-07-28","conditions":"Dry Eye Syndromes","enrollment":200},{"nctId":"NCT06911424","phase":"PHASE3","title":"Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis","status":"RECRUITING","sponsor":"Baxis Pharmaceuticals, Inc.","startDate":"2025-03-21","conditions":"Bacterial Conjunctivitis","enrollment":400},{"nctId":"NCT06792903","phase":"EARLY_PHASE1","title":"YM-101 Eye Drops in the Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-04-23","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT06542497","phase":"PHASE3","title":"Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-08-15","conditions":"Presbyopia","enrollment":569},{"nctId":"NCT05646719","phase":"PHASE3","title":"Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":333},{"nctId":"NCT06349759","phase":"PHASE3","title":"Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2024-04-01","conditions":"Mesopic Vision, Night Vision Loss","enrollment":200},{"nctId":"NCT07449000","phase":"NA","title":"Losartan for Corneal Fibrosis","status":"RECRUITING","sponsor":"Universidad Autonoma de Nuevo Leon","startDate":"2026-02-12","conditions":"Corneal Scarring Fibrosis","enrollment":46},{"nctId":"NCT07095894","phase":"PHASE3","title":"A RCT of Spectacles With Aspherical Lenslets or 0.05% Atropine for Myopia Control","status":"NOT_YET_RECRUITING","sponsor":"Jaeb Center for Health Research","startDate":"2026-03-01","conditions":"Myopia","enrollment":348},{"nctId":"NCT04923841","phase":"NA","title":"Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2021-09-09","conditions":"Myopia","enrollment":579},{"nctId":"NCT07075718","phase":"PHASE2, PHASE3","title":"Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-06-12","conditions":"Glaucoma","enrollment":610},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT07028827","phase":"PHASE3","title":"Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)","status":"RECRUITING","sponsor":"Ocus Innovation Ireland Limited","startDate":"2025-09-01","conditions":"Myopia","enrollment":234},{"nctId":"NCT07400952","phase":"PHASE2","title":"Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus","status":"RECRUITING","sponsor":"Glaukos Corporation","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":100},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT06659549","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD","status":"RECRUITING","sponsor":"Galimedix Therapeutics Inc","startDate":"2025-01-10","conditions":"Geographic Atrophy of the Macula","enrollment":110},{"nctId":"NCT07382453","phase":"PHASE2","title":"Effect of PAE Hydrogel Loaded With tRF-ASO-Exo on Patients With Diabetic Ocular Surface Diseases","status":"NOT_YET_RECRUITING","sponsor":"Affiliated Hospital of Nantong University","startDate":"2026-02-15","conditions":"Diabetic Keratopathy","enrollment":30},{"nctId":"NCT06852768","phase":"PHASE1, PHASE2","title":"Study of d-MAPPS™ Ophthalmic Solution, Safety, Tolerability, and Efficacy in the Treatment of Chronic Ocular Graft-Versus-Host Disease (oGVHD)","status":"RECRUITING","sponsor":"Regenerative Ocular Immunobiologics LLC","startDate":"2025-01-10","conditions":"oGHVD","enrollment":1},{"nctId":"NCT01471184","phase":"NA","title":"The Effects of Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops Compared to Placebo","status":"COMPLETED","sponsor":"Bitop AG","startDate":"2009-09","conditions":"Allergic Rhinitis, Allergic Conjunctivitis","enrollment":46},{"nctId":"NCT07369375","phase":"NA","title":"Efficacy and Safety of VMX Eye Drops for Dry Eye Disease","status":"NOT_YET_RECRUITING","sponsor":"VISUfarma SpA","startDate":"2026-02-02","conditions":"Dry Eye Disease (DED)","enrollment":76},{"nctId":"NCT06213649","phase":"PHASE3","title":"Parasitic Ulcer Treatment Trial","status":"RECRUITING","sponsor":"Jeremy Keenan, MD, MPH","startDate":"2024-07-01","conditions":"Acanthamoeba Keratitis","enrollment":232},{"nctId":"NCT07364370","phase":"NA","title":"Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-02","conditions":"Pediatric Cataract, IOL Implantation, Myopia Progression","enrollment":50},{"nctId":"NCT05826353","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-05-11","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":110},{"nctId":"NCT04505566","phase":"PHASE1","title":"INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen J. Kim, MD","startDate":"2020-11-09","conditions":"Diabetic Retinopathy","enrollment":164},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT03918915","phase":"PHASE3","title":"The Safety and Efficacy of SYD-101 in Children With Myopia","status":"COMPLETED","sponsor":"Sydnexis, Inc.","startDate":"2019-04-24","conditions":"Nearsightedness, Near Sightedness, Near-sightedness","enrollment":852},{"nctId":"NCT06144918","phase":"PHASE2","title":"Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure","status":"COMPLETED","sponsor":"Skye Bioscience, Inc.","startDate":"2023-11-09","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":56},{"nctId":"NCT05066997","phase":"PHASE2, PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2021-10-19","conditions":"Diabetic Macular Edema","enrollment":552},{"nctId":"NCT06172257","phase":"PHASE3","title":"A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oculis","startDate":"2024-03-15","conditions":"Diabetic Macular Edema","enrollment":401},{"nctId":"NCT07329777","phase":"PHASE3","title":"Atropine in the Treatment of Myopia Study in Malaysia","status":"RECRUITING","sponsor":"IDB VisionCare SDN BHD","startDate":"2025-09-17","conditions":"Myopia Progression","enrollment":144},{"nctId":"NCT07313722","phase":"PHASE1","title":"Study Evaluating Safety of BT01001 Ophthalmic Solution","status":"RECRUITING","sponsor":"Beyang Therapeutics Co., Ltd.","startDate":"2025-11-17","conditions":"Healthy","enrollment":32},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT05555589","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2","status":"RECRUITING","sponsor":"ReGenTree, LLC","startDate":"2023-04-11","conditions":"Neurotrophic Keratopathy","enrollment":70},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT06717152","phase":"PHASE3","title":"Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease","status":"COMPLETED","sponsor":"Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd.","startDate":"2024-12-30","conditions":"Dry Eye","enrollment":427},{"nctId":"NCT07220408","phase":"PHASE2","title":"Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis","status":"RECRUITING","sponsor":"Telios Pharma, Inc.","startDate":"2025-10-23","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT06441643","phase":"PHASE2","title":"Next Generation Rocklatan","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2024-09-04","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":426},{"nctId":"NCT04968912","phase":"PHASE2","title":"A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-09-21","conditions":"Sjogren's Syndrome","enrollment":163},{"nctId":"NCT04638660","phase":"PHASE3","title":"Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2020-12-30","conditions":"Dim Light Vision Disturbances","enrollment":144},{"nctId":"NCT04675151","phase":"PHASE2","title":"Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Ocuphire Pharma, Inc.","startDate":"2021-02-15","conditions":"Presbyopia","enrollment":150},{"nctId":"NCT06658002","phase":"PHASE3","title":"Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-09-01","conditions":"Fungal Keratitis, Corneal Ulcer","enrollment":150},{"nctId":"NCT07140783","phase":"PHASE3","title":"OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity","status":"RECRUITING","sponsor":"Ocuphire Pharma, Inc.","startDate":"2025-09-02","conditions":"Vision Loss Night, Vision Disorders","enrollment":200},{"nctId":"NCT04440280","phase":"PHASE2","title":"Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2020-09-16","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":45},{"nctId":"NCT07179055","phase":"PHASE2","title":"An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye","status":"RECRUITING","sponsor":"Vanda Pharmaceuticals","startDate":"2025-10","conditions":"Dry Eye","enrollment":160},{"nctId":"NCT07109609","phase":"PHASE2","title":"Topical Menthol For Tear Secretion","status":"ENROLLING_BY_INVITATION","sponsor":"Reinhold Vieth","startDate":"2025-08-17","conditions":"Healthy, Dry Eyes","enrollment":30},{"nctId":"NCT04622345","phase":"PHASE2","title":"Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies","status":"COMPLETED","sponsor":"Vanda Pharmaceuticals","startDate":"2020-11-21","conditions":"Allergic Conjunctivitis","enrollment":47},{"nctId":"NCT04130802","phase":"PHASE2","title":"OCS-01 in Treating Inflammation and Pain in Post-cataract Patients","status":"COMPLETED","sponsor":"Oculis","startDate":"2019-09-27","conditions":"Inflammation Corneal, Pain, Postoperative","enrollment":153},{"nctId":"NCT07162818","phase":"PHASE4","title":"Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2021-04-28","conditions":"Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment","enrollment":61},{"nctId":"NCT06969001","phase":"PHASE1","title":"Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops","status":"COMPLETED","sponsor":"SCAI Therapeutics","startDate":"2025-05-29","conditions":"Wet Age Related Macular Degeneration","enrollment":48},{"nctId":"NCT07164092","phase":"PHASE2, PHASE3","title":"Efficacy of Topical Atropine Eye Drops for Control of Myopia Progression Among Children Attending Mansoura University Ophthalmic Center","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-09","conditions":"Myopia","enrollment":45},{"nctId":"NCT06523504","phase":"PHASE1, PHASE2","title":"Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control","status":"RECRUITING","sponsor":"Ruihua Wei","startDate":"2024-02-01","conditions":"Myopia","enrollment":410},{"nctId":"NCT05938699","phase":"PHASE2, PHASE3","title":"Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2023-12-12","conditions":"Open Angle Glaucoma","enrollment":18},{"nctId":"NCT07154147","phase":"PHASE4","title":"Oral vs IV Sedation for Cataract Surgery in Older Adults","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-08-12","conditions":"Cataract Surgery, Sedation, Cognition Function","enrollment":20},{"nctId":"NCT05913232","phase":"PHASE2","title":"Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"D. Western Therapeutics Institute, Inc.","startDate":"2023-08-28","conditions":"Glaucoma Open-Angle Primary, Ocular Hypertension","enrollment":201},{"nctId":"NCT06637527","phase":"PHASE2","title":"The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain","status":"TERMINATED","sponsor":"Okyo Pharma Ltd","startDate":"2024-10-15","conditions":"Neuropathic Pain","enrollment":18},{"nctId":"NCT07124143","phase":"NA","title":"The Effect of Platelet-Rich Plasma on Wound Healing After Gingivectomy","status":"COMPLETED","sponsor":"Duygu Kilic","startDate":"2021-06-02","conditions":"Gingival Overgrowth","enrollment":38},{"nctId":"NCT07120308","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2021-09-15","conditions":"Corneal Epithelial Defect","enrollment":28},{"nctId":"NCT02484716","phase":"PHASE2","title":"Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2015-06","conditions":"Telangiectasia, Hereditary Hemorrhagic, Osler Rendu Disease","enrollment":58},{"nctId":"NCT06209281","phase":"PHASE3","title":"A Phase III Clinical Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-05-13","conditions":"Myopia","enrollment":526},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777},{"nctId":"NCT07068958","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"ORA, Inc.","startDate":"2025-08-01","conditions":"Dry Eye Disease (DED)","enrollment":200},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT06975748","phase":"PHASE2","title":"A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-06-12","conditions":"Neurotrophic Keratitis","enrollment":48},{"nctId":"NCT06865144","phase":"PHASE4","title":"Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT","status":"RECRUITING","sponsor":"East Coast Institute for Research","startDate":"2025-06-27","conditions":"Primary Open Angle Glaucoma or Ocular Hypertension","enrollment":70},{"nctId":"NCT03911271","phase":"PHASE2","title":"Low-dose Atropine for the Prevention of Myopia Progression in Danish Children","status":"COMPLETED","sponsor":"Line Kessel","startDate":"2019-05-30","conditions":"Myopia","enrollment":97},{"nctId":"NCT06818487","phase":"NA","title":"Ganyan-1 in Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tongren Hospital","startDate":"2025-07-01","conditions":"Dry Eye, TCM","enrollment":219},{"nctId":"NCT07012512","phase":"NA","title":"Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children","status":"NOT_YET_RECRUITING","sponsor":"Mansoura University","startDate":"2025-06-01","conditions":"Pupillary Constriction, Accomodation","enrollment":60},{"nctId":"NCT04734210","phase":"PHASE2","title":"Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-07","conditions":"Dry Eye Disease","enrollment":139},{"nctId":"NCT05608837","phase":"PHASE2","title":"Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quan Dong Nguyen","startDate":"2023-05-26","conditions":"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative","enrollment":28},{"nctId":"NCT06960629","phase":"","title":"The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Pseudophakic Bullous Keratopathy, Glaucoma","enrollment":50},{"nctId":"NCT04030962","phase":"PHASE1, PHASE2","title":"A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-03-04","conditions":"Dry Eye Disease, Dry Eye Syndrome","enrollment":292},{"nctId":"NCT06969586","phase":"","title":"The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy","status":"ENROLLING_BY_INVITATION","sponsor":"University Hospital Dubrava","startDate":"2025-04-01","conditions":"Fuchs Endothelial Corneal Dystrophy, Cataract, Glaucoma","enrollment":50},{"nctId":"NCT04734197","phase":"PHASE2","title":"A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Surface Ophthalmics, Inc.","startDate":"2021-01-11","conditions":"Dry Eye Disease","enrollment":349},{"nctId":"NCT04565756","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Tolerability of EXN407","status":"COMPLETED","sponsor":"Exonate Limited","startDate":"2020-11-05","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT06956846","phase":"PHASE4","title":"Efficacy of Topical Insuline in Corneal Epithelial Healing Post PRK","status":"NOT_YET_RECRUITING","sponsor":"Hotel Dieu de France Hospital","startDate":"2025-04-25","conditions":"Corneal Epithelial Wound Healing","enrollment":100},{"nctId":"NCT06100939","phase":"PHASE3","title":"Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epion Therapeutics","startDate":"2023-10-30","conditions":"Keratoconus","enrollment":400},{"nctId":"NCT06948357","phase":"PHASE2","title":"Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients","status":"RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2025-03-24","conditions":"Presbyopia","enrollment":119},{"nctId":"NCT05992922","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of IC265 Ophthalmic Solution for Dry Eye in Adult Participants","status":"TERMINATED","sponsor":"Iacta Pharmaceuticals","startDate":"2023-10-17","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03733899","phase":"NA","title":"An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort","status":"COMPLETED","sponsor":"Johnson & Johnson Vision Care, Inc.","startDate":"2018-11-07","conditions":"Visual Acuity","enrollment":22},{"nctId":"NCT03298815","phase":"PHASE1, PHASE2","title":"Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)","status":"COMPLETED","sponsor":"University of Utah","startDate":"2019-12-20","conditions":"Ocular Graft Versus Host Disease","enrollment":15},{"nctId":"NCT06906198","phase":"PHASE1","title":"Pharmacokinetics of VVN461 Ophthalmic Solution","status":"COMPLETED","sponsor":"VivaVision Biotech, Inc","startDate":"2023-03-01","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT06389110","phase":"PHASE3","title":"Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-03-15","conditions":"Myopia, Myopia, Progressive","enrollment":123},{"nctId":"NCT06514612","phase":"PHASE3","title":"LIDRISE Study: A Phase 3 Study on the Efficacy and Safety of STN1013800 (Oxymetazoline HCl 0.1% Eye Drops, Single Dose) in the Treatment of Acquired Blepharoptosis.","status":"RECRUITING","sponsor":"Santen SAS","startDate":"2024-12-30","conditions":"Acquired Blepharophimosis","enrollment":234},{"nctId":"NCT06879782","phase":"PHASE3","title":"Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Lunan Better Pharmaceutical Co., LTD.","startDate":"2024-03-28","conditions":"Dry Eye Disease (DED)","enrollment":820},{"nctId":"NCT03193333","phase":"PHASE3","title":"PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2017-11-06","conditions":"Primary Open-angle Glaucoma","enrollment":51},{"nctId":"NCT03865160","phase":"PHASE2, PHASE3","title":"Low-dose Atropine for Myopia Control in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Eye Hospital, Freiburg","startDate":"2021-10-19","conditions":"Myopia, Progressive","enrollment":302},{"nctId":"NCT06851364","phase":"PHASE2","title":"Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants","status":"COMPLETED","sponsor":"International Islamic University Malaysia","startDate":"2022-10-30","conditions":"Dry Eye","enrollment":45},{"nctId":"NCT06045299","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia","status":"COMPLETED","sponsor":"Corxel Pharmaceuticals","startDate":"2023-09-27","conditions":"Presbyopia, Near Vision, Miosis","enrollment":300},{"nctId":"NCT05379855","phase":"NA","title":"A-eyedrops on Ocular Alignment and Binocular Vision","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-03-02","conditions":"Exotropia, Exophoria, Myopia","enrollment":339},{"nctId":"NCT06100952","phase":"PHASE3","title":"Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Epion Therapeutics","startDate":"2023-11-01","conditions":"Keratoconus","enrollment":400},{"nctId":"NCT06822608","phase":"PHASE4","title":"Evaluation of Dexpanthenol and Hyaluronic Acid Eye Drops on Corneal Epithelialization After Trans Epithelial PRK","status":"NOT_YET_RECRUITING","sponsor":"National and Kapodistrian University of Athens","startDate":"2025-02","conditions":"Corneal Epithelial Wound Healing","enrollment":68},{"nctId":"NCT06132035","phase":"PHASE1","title":"Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration","status":"RECRUITING","sponsor":"Caregen Co. Ltd.","startDate":"2023-12-22","conditions":"Age-related Wet Macular Degeneration","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Saline/ Benzalkonium Chloride (BAK) Ophthalmic Solution"],"phase":"phase_3","status":"active","brandName":"Placebo Eyedrops","genericName":"Placebo Eyedrops","companyName":"Jaeb Center for Health Research","companyId":"jaeb-center-for-health-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo eyedrops contain no active pharmaceutical ingredient and produce therapeutic effects through the placebo effect. Used for Control comparator in ophthalmic clinical trials (specific indication depends on concurrent active treatment arm).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}